Glaukos Corporation

GKOS

$161.53

Updated: 22/09/2026, 14:57:16

Market Cap

$9.53B

Sector

Healthcare

Industry

Medical - Devices

Country

Stock valuation chart

One-year closing share-price history for GKOS

Company Profile

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

USD

NYSE

CEO: Thomas William Burns

Employees: 1,094

https://www.glaukos.com

Asset Summaries

Latest generated summaries for GKOS

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for GKOS.

Share price: $161.53
Market cap: $9.53B
Exchange: NYSE
Currency: USD
CEO: Thomas William Burns
Employees: 1,094
IPO date: 25/06/2015
Beta: 0.767
Last dividend: $0.00
Day range: $160.45 – $162.86
52-week range: $73.16 – $191.62
1-day performance: -1.39%
1-year performance: 120.79%
Current drawdown (1Y): -15.70%
CIK: 0001192448
CUSIP: 377322102
ISIN: US3773221029
Created: 07/12/2025, 04:14:39
Last update: 22/09/2026, 14:57:16

Track Glaukos Corporation with an AI analyst

See which prediction-market events move GKOS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to GKOS from your Railway `news_articles` table.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Zacks Investment Research • STOCK • 05/06/2026, 17:16:14

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Zacks Investment Research • STOCK • 30/04/2026, 13:55:14

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 30/04/2026, 01:21:32

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research • STOCK • 30/04/2026, 00:00:22

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Zacks Investment Research • STOCK • 20/03/2026, 11:35:34

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Zacks Investment Research • STOCK • 19/03/2026, 13:31:21

Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook

Zacks Investment Research • STOCK • 18/02/2026, 12:55:15

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 18/02/2026, 00:14:57

Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research • STOCK • 17/02/2026, 20:01:32

Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates

Zacks Investment Research • STOCK • 17/02/2026, 19:25:26